Literature DB >> 19532126

The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt.

Rania Nancy Rabie1, Massimo Cazzaniga, Francesco Salerno, Florence Wong.   

Abstract

OBJECTIVES: The clinical significance of diastolic dysfunction in cirrhosis, a feature of cirrhotic cardiomyopathy, is unclear. The aim of this study was to assess the utility of E/A ratio, an indicator of diastolic dysfunction, to predict ascites clearance and mortality after transjugular intrahepatic portosystemic stent shunt (TIPS) insertion.
METHODS: A total of 101 cirrhotic patients who received TIPS had pre-TIPS assessments of demographics, severity of liver dysfunction (Child-Pugh and Model for End-Stage Liver Disease (MELD) scores), renal function, hemodynamics, and cardiac function (two-dimensional echocardiography). An E/A ratio of < or =1 was used to indicate diastolic dysfunction. Patients were followed-up for a mean period of 24.6+/-2.4 months post TIPS.
RESULTS: A total of 41 patients with an E/A ratio of < or =1 (group A), and 60 patients with an E/A ratio of >1 (group B) were studied. Group A had significantly higher MELD scores (14.0+/-1.0 vs. 11.4+/-0.8; P=0.03), because of higher serum creatinine levels (107+/-5 vs. 86+/-6 micromol/l; P<0.01). There was no difference in pre-TIPS systemic hemodynamics, systolic function, or portal pressure between the two groups. After TIPS, more patients in group B had ascites clearance (log rank, P=0.038), and the same patients had a higher probability of survival (log rank, P=0.046). There were three post-TIPS cardiac deaths in group A only. A multivariate analysis showed that an E/A of ratio < or =1 was predictive of slow ascites clearance (hazard ratio=7.3, 95% confidence interval=1.3-40.7, P=0.021) and death after TIPS (hazard ratio=4.7, 95% confidence interval=1.1-20.2, P=0.035).
CONCLUSIONS: Diastolic dysfunction, indicated by reduced E/A ratio, is prevalent in advanced cirrhosis and is associated with reduced ascites clearance and increased mortality post TIPS, possibly related to worsening of hemodynamic dysfunction in the post-TIPS period.

Entities:  

Mesh:

Year:  2009        PMID: 19532126     DOI: 10.1038/ajg.2009.321

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  46 in total

1.  Cardiac changes in pediatric liver transplant recipients: are they truly irreversible?

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2016-02-16       Impact factor: 6.047

Review 2.  Does cirrhotic cardiomyopathy exist? 50 years of uncertainty.

Authors:  Pierpaolo Pellicori; Concetta Torromeo; Angela Calicchia; Alessandra Ruffa; Martina Di Iorio; John G F Cleland; Manuela Merli
Journal:  Clin Res Cardiol       Date:  2013-09-01       Impact factor: 5.460

3.  Cirrhosis-related changes in left ventricular function and correlation with the model for end-stage liver disease score.

Authors:  Xiaopeng Li; Shanshan Yu; Lu Li; Donggang Han; Shejiao Dai; Ya Gao
Journal:  Int J Clin Exp Med       Date:  2014-12-15

4.  Can non-invasive measurements aid clinical assessment of volume in patients with cirrhosis?

Authors:  Andrew Davenport; Banwari Argawal; Gavin Wright; Konstantinos Mantzoukis; Rumyana Dimitrova; Joseph Davar; Panayota Vasianopoulou; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2013-08-27

5.  The impact of left ventricular hypertrophy on survival in candidates for liver transplantation.

Authors:  Sachin Batra; Victor I Machicao; John S Bynon; Shivang Mehta; Rajasekhar Tanikella; Michael J Krowka; Steven Zacks; James Trotter; Kari E Roberts; Robert S Brown; Steven M Kawut; Michael B Fallon
Journal:  Liver Transpl       Date:  2014-06       Impact factor: 5.799

Review 6.  Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients.

Authors:  Suehana Rahman; Susan V Mallett
Journal:  World J Hepatol       Date:  2015-03-27

7.  Speckle tracking echocardiography in cirrhosis: is it ready for prime time?

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2014-01-09       Impact factor: 6.047

8.  Assessment of diastolic function in the management of patients with cirrhosis.

Authors:  Søren Møller
Journal:  Hepatol Int       Date:  2014-07-27       Impact factor: 6.047

9.  Diastolic dysfunction characterizes cirrhotic cardiomyopathy.

Authors:  Piyush O Somani; Qais Contractor; Ajay S Chaurasia; Pravin M Rathi
Journal:  Indian Heart J       Date:  2014-07-23

Review 10.  Left ventricular function assessment in cirrhosis: Current methods and future directions.

Authors:  Francisco Sampaio; Joana Pimenta
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.